About Shionogi

  1. TOP > 
  2. About Shionogi > 
  3. Medium-term business plan

Medium-term business plan

Announced on March 28, 2014

The Medium-Term Business Plan of SHIONOGI "SGS2020"
(Start from April 2014)

Growth Strategy toward 2020. Shionogi Growth Strategy 2020(SGS2020)

In April 2014 we launched the Shionogi Growth Strategy 2020 (SGS2020). SGS2020 sets our vision to grow as a drug discovery-based pharmaceutical company through clear priorities and focused resourcing, growth led by FIC and LIC compounds, and continued improvement of business operations.
In May 2016, we announced the rolling plan for FY2018, with targets of 125B yen of ordinary income and 15% of ROE. We aim to achieve our SGS2020 final-year targets for ordinary income and ROE two years early. As a result, in October 2016, we updated our FY2020 vision and targets accordingly.

*1 First in Class (FIC) : Innovative medicines with particularly high novelty and usability that can change the existing therapeutic paradigm significantly

*2 Last in Class (LIC) : Unrivaled medicines with clear superiority over others with the same mechanism of action

Updates to SGS2020

Announced October 31, 2016


Our vision is to be a company that actualizes its corporate mission – Shionogi’s Purpose – globally: Shionogi strives constantly to supply the best possible medicine to protect the health and wellbeing of the patients we serve.

Growth Strategy for 2020

Grow sustainably as a drug discovery-based pharmaceutical company contributing to a more vigorous society through improved healthcare

Grow as a drug discovery-based  pharmaceutical company

Social Challenges that Shionogi Strives to Address

Creating a more vigorous society

  • Help people who are isolated due to pain/suffering to re-enter society
  • Provide relief from psychological uncertainty allowing fulfillment of one’s innate ability
  • Maintain the dignity of the individual through all the stages of life

Protecting people from the threat of infectious diseases

  • Develop new drugs against infectious diseases that lack effective medical treatments
  • Reduce outbreaks of bacterial and viral resistance by promoting proper use of anti-infective drugs

KPIs for SGS2020

KPIs for SGS2020

Balancing Shareholder Return and Investment for Our Future

Maximize enterprise value by balancing three key factors, reflecting growth commensurate with our contributions to a more vigorous society

Balancing Shareholder Return and Investment for Our Future

Forward-Looking Statements

  • Forecast or target figures in this material are neither official forecasts of earnings and dividends nor guarantee of target, achievement and forecasts, but present the midterm strategies, goals and visions. Official earnings guidance should be referred to in the disclosure of the annual financial report (kessan tanshin) in accordance with the rules set by Tokyo Stock Exchange.
  • This materials may contain so-called “forward-looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
  • Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency’s examination period, obtaining regulatory approvals; domestic and foreign healthcare reforms; trend toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
  • For products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
  • Shionogi disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
  • This material is presented to inform stakeholders of the views of Shionogi's management but should not be relied on solely in making investment and other decisions.
  • You should rely on your own independent examination of us before investing in any securities issued by our company. Shionogi shall accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding or changes of target figures or any other use of this material.
  • This English material was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.

page top